Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV labetalol versus hydralazine for severe hypertension in preeclampsia with severe features
PACTR202607596296076Not yet recruiting
- Sponsor
- Dr Casmir Madubuko
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in preeclampsia comparing Intravenous labetalol with Intravenous hydralazine (2 arms). Primary endpoint: Achievement of target blood pressure control. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
labetalolhydralazine
03
Conditions
preeclampsia
Beyond the preview
Go deeper on PACTR202607596296076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607596296076.